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Objectives: The aim of this study was to analyze and describe process and outcomes of
two pilot assessments based on the HTA Core Model, discuss the applicability of the
model, and explore areas of development.
Methods: Data were gathered from HTA Core Model and pilot Core HTA documents, their
validation feedback, questionnaires to investigators, meeting minutes, emails, and
discussions in the coordinating team meetings in the Finnish Office for Health Technology
Assessment (FINOHTA).
Results: The elementary structure of the HTA Core Model proved useful in preparing
HTAs. Clear scoping and good coordination in timing and distribution of work would
probably help improve applicability and avoid duplication of work.
Conclusions: The HTA Core Model can be developed into a platform that enables and
encourages true HTA collaboration in terms of distribution of work and maximum
utilization of a common pool of structured HTA information for national HTA reports.
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Work Package 4 (WP4) of the EUnetHTA Project (6) devel-
oped a standardized structure for health technology assess-
ments, that is, the HTA Core Model (4;5). Its novel elementary
structure allows rigorous production and transparent presen-
tation of health technology assessment (HTA) information
(7). The HTA Core Model consists of 9 domains (Table 1).
Each domain is divided into more specific topics, and further
into issues in the form of generic questions. The combination
of domain, topic, and issue defines an assessment element, the
basic unit in the Model. The elements are divided into core
and noncore elements based on their importance and transfer-
ability (7). The Model guides the HTA doers first to consider
the relevance of each assessment element for the technology.
For each relevant element, the generic question is translated
into a specific question concerning the technology. A Core
HTA is the compilation of the questions and answers of rele-
vant core elements for a specific technology, and a summary
chapter.
The EUnetHTA Project piloted the HTA Core Model
with two topics: a therapeutic intervention and a diagnostic
technology. These pilot Core HTAs (2;3) tested the concept
and structure of the Model and the adequacy of the assess-
ment elements. Because piloting primarily aimed at experi-
menting the Model and its use, not all issues were assessed
with full scientific thoroughness. Therefore, the pilot Core
HTAs should not be considered as stand-alone HTAs or used
in actual decisions in health care.
The Finnish Office for Health Technology Assessment
(FINOHTA) guided the production of the Core Model and the
pilot HTAs. Practical guidance for future work is compiled
in a Handbook (8).
AIMS AND OBJECTIVES
This article analyzes and describes the processes and out-
comes of the two pilot Core HTAs that were used to test the
HTA Core Model. The focus is on the essential points for us-
ing the Model: scoping and framing, assessing relevance of
generic issues, translating issues into research questions, and
reporting answers in the structured format. We also discuss
some relevant problems encountered during the two pilot
Core HTA projects, their solutions, and the applicability of
the HTA Core Model.
Table 1. Domains in the HTA Core Model
1. Health problem and current use of the technology
2. Description and technical characteristics of the technology
3. Safety
4. Effectiveness (including Accuracy)
5. Costs and economic evaluation
6. Ethical analysis
7. Organizational aspects
8. Social aspects
9. Legal aspects
HTA, health technology assessment.
STRUCTURE AND METHODS
The pilot Core HTAs on drug eluting stents (DES) and
multislice computed tomography (MSCT) in coronary an-
giography were based on draft versions of the HTA Core
Model (4;5). Description of the Model and its domain
specific guidance are presented elsewhere in this jour-
nal (7). Supplementary Table 1, which is available at
www.journals.cambridge.org/thc2009002, presents the num-
ber of investigators and reviewers in each of the domain
specific working teams. The task of the teams was to select
relevant questions in the Model and produce evidence based
answers to them. Internal and external feedback was sought
during a validation process.
Data for this article were gathered from the first public
drafts of the two pilot Core HTAs (2;3), their validation feed-
back, a questionnaire sent to investigators in domain teams
(10 of 18 replied), minutes of project and team meetings,
emails, and direct discussions among EUnetHTA coordina-
tors and primary investigators at FINOHTA.
RESULTS
Topic Selection
Following a two-step, Web-based voting procedure, orga-
nizations participating in WP4 selected DES (intervention)
and MSCT (diagnostic) as pilot topics out of twenty propos-
als for interventions and fourteen proposals for diagnostic
technologies. Five criteria were considered in the selection:
European scope, transferability, relevance for several do-
mains, feasibility of carrying out the assessment, and voter’s
preference (Supplementary Table 2, which is available at
www.journals.cambridge.org/thc2009002).
Scoping and Framing
Comparing drug eluting to bare metal stents was a meaning-
ful scope for the DES pilot. This framing was used in three
domains, that is, Description and technical characteristics,
Effectiveness, and Costs (Table 1: Domains 2, 4, and 5).
Other domains framed at least some of their questions more
broadly: they considered stents in general, cardiac interven-
tions (including coronary bypass surgery), or even medical
devices at large in their answers. For instance, in the Social
domain, the research question about postintervention work
ability referred to studies comparing stents with angioplasty.
In the Organizational aspects domain, the description of in-
formation flow in integrated patient pathways was not spe-
cific to DES patients but applicable to any patient undergoing
surgery.
Scoping for MSCT coronary angiography had different
problems. This noninvasive imaging modality could replace
some invasive coronary angiographies (ICA) in diagnosing
coronary artery disease (CAD). ICA is the gold standard for
CAD diagnoses, but for MSCT, ICA is not the clinically
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most relevant comparison test. Unlike MSCT, ICA can also
be extended to a therapeutic intervention: the obstructed ves-
sels can be opened during the procedure. The investigators
therefore identified the following scope for their assessment:
comparing a diagnostic pathway with and without MSCT in
patients with low to moderate risk of CAD. This scope was
strictly followed in the Effectiveness domain, but less so in
other domains.
Assessing the Relevance of the
Assessment Elements
The draft Intervention Model contained 163 assessment el-
ements; on average 18 (range, 6–29) per domain. Ninety of
them were labeled as core elements. The investigators in the
DES pilot considered 77 percent of all elements and 79 per-
cent of the core elements to be relevant in the context of DES.
The percentages were smaller than in MSCT, partly because
elements in the Safety domain were not specifically assessed
in DES.
The draft Diagnostic Model contained 158 assessment
elements, 87 of them belonging to the core. Investigators in
the MSCT pilot considered 90 percent of all elements and
89 percent of the core elements relevant in their context. All
Effectiveness and Organizational elements were considered
relevant in both pilot HTAs.
From Issues to Research Questions
Typically, one generic issue in an assessment element was
translated into one specific research question. Among the 117
generic issues answered in the DES pilot, 6 (5 percent) were
translated into several research questions. In the MSCT pilot,
11 of 128 answered issues (9 percent) were each translated
into two to four research questions.
We asked the investigators how easy it was to translate
the generic questions in the Model into technology-specific
research questions. The task was simple according to eight
of ten respondents. Investigators of the Ethical analysis do-
main noticed that formulating the question is a crucial step
requiring careful thought, or even an analysis of the stake-
holders’ values attributed to the technology and its use. Some
believed that the categorization or naming of generic issues
hindered translation, which led to proposed changes in the
Model.
Finding Information for Answers
A systematic literature review was the standard method used
to find information to answer questions. An information
specialist at FINOHTA designed and performed the basic
searches, with search terms covering the disease and the tech-
nology. The teams were urged to supplement these with more
specific searches. In some instances, a systematic review was
clearly infeasible, or even unnecessary. For instance, answers
to the questions about incidence or the current management
practices of CAD were based on information derived from re-
cent HTAs or guidelines, instead of systematically reviewing
original research. Some investigators had recently performed
traditional HTAs, or systematic reviews on DES or MSCT,
and could transfer relevant pieces of information directly into
the pilot Core HTAs. Earlier work was used in domains 3, 4,
and 5 of the DES pilot and in domains 1, 2, 3, and 5 of the
MSCT pilot.
Due to the lack of published studies, the Organizational
and Social domain teams did their own research, mainly us-
ing semistructured or structured interviews of experts, key
officials, clinicians, or patients. The Costs and economic
evaluation domain used modeling. Compiling information
from national registries, databases, manufacturers’ informa-
tion sheets, and standard protocols provided answers espe-
cially to domains 1, 2, and 9. Answers in the Ethical aspects
domain were based on published data of stakeholder views,
but the final output usually required additional primary in-
quiries.
The MSCT pilot could use results created earlier for
DES. Five structured pieces of information from the DES
Core HTA, about characterization, symptoms, incidence, and
mortality of CAD, were exploited as such, or in a slightly
modified form, in the MSCT Core HTA.
Reporting the Results
Half of the Domain teams managed to answer all relevant
issues. In the DES pilot, 10 of 126 relevant issues were left
unanswered. Six of them belonged to the core elements (8
percent of all relevant core elements). In the MSCT pilot, an-
swers to 17 of the 143 relevant issues were missing, 6 of these
being core elements (8 percent of all relevant core elements).
The typical reason given was time pressure. Lack of capacity
or motivation could also explain this, as some Domain teams
had few substance or methods experts. The Safety domain
teams did not produce any text for DES, considering it too
artificial to discuss safety and effectiveness issues separately
in this particular context.
Preparing the Summary
No summary was written for the DES pilot. Afterward, dis-
cussions in WP4 and the validation feedback underlined the
need for a summary. The General Design team of the MSCT
pilot decided that brief domain summaries were compiled
by the editor into a two-page summary for the whole Core
HTA document. No conclusions or recommendations were
included.
Validation
The first public draft of the Core HTA on DES was pub-
lished in June 2007 and on MSCT in July 2008. These
documents were submitted for validation to EUnetHTA par-
ticipants and INAHTA members by email. Public feedback
was sought with a separate questionnaire on the EUnetHTA
Web site and personal reminders to organizations. The
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Table 2. Validation Results
Statements in the Validation Questionnaire DES MSCT
The structure of the Core HTA is feasible 89% 78%
The issues cover the area adequately 84% 68%
The results are useful in decision making 68% 65%
Note. Percentage of respondents that agreed with the statements in the
validation of the pilot core health technology assessments (HTAs) on drug
eluting stents (DES) and multislice computed tomography (MSCT) in
coronary angiography.
validation questionnaires covered the feasibility of the struc-
ture from the readers’ point of view, adequacy of the research
questions, and the usefulness of the answers in informing
policy. There were twenty-three EUnetHTA/INAHTA re-
spondents on DES and seventeen on MSCT, and (including
collated responses from ISPOR) eight public feedback re-
spondents on DES and two on MSCT. The responses were
mainly positive, and the work was considered to be promis-
ing (Table 2). Supplementary Table 3, which is available at
www.journals.cambridge.org/thc2009002, gives an overview
of the problems detected in the validation, and Supplemen-
tary Table 4, which is available at www.journals.cambridge.
org/thc2009002, presents domain-specific results.
DISCUSSION
Scoping and Framing the Topic
The scope of the assessment, in terms of explicit definition of
the patients, intervention, comparison, and outcomes should
be identical throughout a Core HTA. Otherwise, the informa-
tion provided in various domains might not be commensu-
rate. In the DES pilot, the scope was drug eluting versus bare
metal stents in CAD, and Domain teams kept to this. In the
MSCT pilot, the scope was determined to be a comparison of
a management pathway with, versus without MSCT, in pa-
tients with low risk of CAD. The scope was chosen because
it was considered important to assess the value of MSCT
in ruling out CAD and reducing the need for ICA in low-
risk patients. The selected scope, however, was not observed
by all Domain teams. The Costs domain found that there
was insufficient evidence to assess the cost-effectiveness of
MSCT compared with not using MSCT in the target popula-
tion, which would in practice mean a blank chapter for this
domain. However, for the purpose of testing the HTA Core
Model, it re-defined its objectives to verify the basis for the
commonly asserted statement that MSCT is cost-effective
compared with ICA in a specific patient population.
Scoping study questions in the pilot projects thus had
various rationales, clinical relevance being the most obvious.
At times, a scoping is selected because systematic reviews
are available. The problem with this kind of opportunistic
scoping is that it may introduce an unbalanced HTA where
problems important for implementation are left out.
When the scope of the assessment is clear, it is possible
to let the Domain teams frame their research questions dif-
ferently. Different framing means that research questions can
be expanded to include a broader category, still retaining the
scope. For example, drug eluting stents represent stents in
general. Stenting is a coronary intervention like angioplasty
and coronary bypass; they all belong to cardiac interventions.
Often a technology shares problems of the group it belongs to.
Drug eluting stents are devices that release a drug; their drug
licensing issues can be shared with drugs in general. MSCT
shares safety issues of computer tomography technologies in
general, or any imaging modality using radiation.
Variation in framing across the Domains of a Core HTA
or across single question answer-pairs is not a problem if ex-
plicitly reported. The Social domain of the DES pilot broad-
ened their frame from the strict drug eluting versus bare metal
stent comparison to allow assessment of the social aspects
of stents in general, as the team assumed that the impact on
a patient would be largely independent of stent type. In the
absence of research in an area, presenting evidence from a
differently framed, but well researched, angle may be useful,
although the information might not be directly applicable.
Overlaps Across Domains
Half of the generic questions in the Model are obviously in-
terrelated with each other. Questions similar at first glance
usually should be answered from the viewpoint of each do-
main. For example, the element of autonomy and informed
consent in the Ethical analysis domain reflects the views of
patients themselves; in the Legal domain, it is a formal pre-
requisite to invasive procedures.
Obvious linkages between elements call for an organized
HTA process: some assessment elements use information
from elements in other domains. Knowledge about disease
incidence is required when translating generic questions into
actual research questions in Effectiveness Domain, and effec-
tiveness and safety data are needed for Costs and Economic
Evaluation domain answers. Linkages between elements are
a problem only if real overlapping leads into duplication of
work. Future Core HTAs must start by identifying elements
requiring input from several domains to agree on timing and
division of labor.
Core Elements
Each element in the HTA Core Model has been assigned
a category for importance and transferability. In DES and
MSCT pilots, some domain teams made a topic-specific re-
assessment of these categories, although it is, at the moment,
not considered as a standard feature of Core HTAs. They
encountered the same difficulties in the assessment of impor-
tance and transferability as the Model doers. For example,
in the Ethical analysis domain, the authors believed that al-
most every element could be defined as important from some
stakeholder’s point of view. Transferability was considered
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not the property of the question alone while it depends very
much on how extensive and detailed the answer will be. De-
tailed incidence data per country may be more transferable
than aggregate figures for Europe. An assessment element de-
scribing variation in the use of a technology in several coun-
tries, as occurred in DES, may importantly hint at over- or
underuse of the technology locally. In the Costs domain of the
MSCT pilot, results were obviously not transferable to other
contexts, but investigators considered the issues to belong in
the core; unit costs are rarely transferable as such, but they
provide a useful perspective to local data. It is the HTA user
who eventually determines the transferability of the infor-
mation presented in a Core HTA. An Italian decision maker
finds Italian cost data transferable, whereas his/her Swedish
colleague does not. When the Swedish reader gets cost in-
formation from seven European countries, he might consider
these partially transferable or useful for putting his own costs
into perspective, even without Swedish data. Transferabil-
ity assessment is further discussed by Turner et al. in this
journal (9).
Coordination
The shared opinion of the pilot HTA investigators was that, in
the future too, it is possible, in principle, to divide the work
between HTA agencies. One or two domains per agency
would be a natural way to share Core HTAs. Contributions
could also be less; only some topics or issues from one do-
main. Strong coordination of the work by professional project
leaders was considered essential if agencies are to share the
work. This requires monitoring to ensure that the Domain
teams provide answers to all relevant questions, with the
same scope, in a reasonable order and without duplication
of work. Editors need to guarantee congruence and organize
quality control in terms of methodological validity, com-
prehensiveness, and timeliness. English language checks are
important in this multilingual environment with few native
English speakers.
Communication remains a major issue when performing
network HTAs. Conference calls or e-meetings were planned
for pilot HTAs, but proved impractical at an early stage and
were seldom used. However, with increasing experience, the
performance and utility of firmly organized e-meetings was
improving. Working only through email was believed to be
tedious. The new communication platform proposed by the
Information Management System of the EUnetHTA Collab-
oration (1) might provide a solution for the future.
Reporting Core HTAs. In the feedback for both pilot
Core HTAs, several respondents pointed out poor reporting.
They called for justification of methods used and information
on search strategies, inclusion criteria, and study quality. The
common methodology chapter for the whole domain was
considered inadequate. Readers generally preferred having
the methods described separately for each research question.
Some of the introductory texts on domains in the pilot HTAs
were deficient: definitions or focus were missing, or the in-
troduction already presented a summary of the answers.
The pilot Core HTAs reported results as question-
answer pairs. This was generally considered to improve
consistency and clarity. On the other hand, the authors of the
Ethical analysis domain did not find the splitting of results a
good solution. A balanced discussion, written in HTA prose,
was preferred. An ethical analysis was considered more
complex than a set of answers to specific technical research
questions. Additionally, the answers usually required some
background information for the reader to understand the
message. This means we would need to link identical
pieces of text containing background information, to several
answers. In traditional paper format, this redundancy is not
ideal. As Core HTAs are ultimately electronic collections
of assessment elements (with a summary text), in the form
of question-answer pairs, such redundancy is acceptable
and even necessary. Because each element should be
understandable alone, cross-references to text, for example,
“see above,” are not encouraged.
Readers’ View. There were varying opinions in the
validation feedback on the required extensiveness and level
of detail of the Core HTAs. This probably reflected the two
reader groups; researchers and decision makers. Researchers,
mainly HTA producers, preferred the elementary structure
and detailed information on sources and quality of evidence.
Decision makers found the current 200-page format too ex-
tensive. One respondent even asked for separating issues
relevant for decision makers and providing details in an ap-
pendix. People had different views about the role of the sum-
mary chapter in a Core HTA. Suggestions ranged from a
collection of domain results to a single conclusion or a rec-
ommendation with pragmatic instructions for action.
Future Use of the Core Model
The domain-specific lists of generic questions were consid-
ered useful checklists, even when starting to prepare a tra-
ditional HTA report. Flexible selection of issues, including
noncore issues, is necessary. Instead of doing a whole Core
HTA, several people who had participated in the pilot Core
HTAs considered it possible to provide answers, at least to
some of the assessment elements in English when making a
local HTA, and sharing them through the EUnetHTA Collab-
oration. This would gradually build toward a joint European
pool of structured HTA information. Using assessment ele-
ments in the pool, as such or in a slightly modified form, is
an apparent benefit that might save resources.
The HTA Core Model is evolving; new issues, and even
domains, can be brought into the Model, and others com-
bined or removed. The decision in the DES pilot to exclude
all issues in the Safety domain was motivated by the strong
linkage between safety issues and effectiveness. Therefore
it was asked, whether a separate Safety domain was nec-
essary. After considerations, it was determined that safety
INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 25:SUPPLEMENT 2, 2009 25
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S026646230999064X
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 14:44:23, subject to the Cambridge Core terms of use, available at
Pasternack et al.
issues deserve their own domain, separate from the Effec-
tiveness domain in the HTA Core Model. This was appar-
ent already in the MSCT pilot. Safety is not simply the
inherent, unwanted effects of the intervention to the pa-
tient, but also includes preventable, performance-related is-
sues, and possible risks caused to practitioners and public
health.
The HTA Core Model represents a major shift in the
content and work processes of a traditional HTA. Not all HTA
agencies envisage sharing work with other HTA units yet.
Some agencies already foresee true European collaboration,
provided that the future online system of the HTA Core Model
truly facilitates group work.
The role of Core HTAs in decision making needs further
pilot testing and discussions. The overall opinion of readers
and investigators was that a Core HTA should be an easily
shared and updated package of HTA information, with suf-
ficiently detailed and extensive presentation, and it should
provide information, not instruction, for decision making in
health care.
CONCLUSION AND RECOMMENDATION
The HTA Core Model was generally welcomed as a means
to facilitate European HTAs and improve their quality. Pi-
lot Core HTAs were created for the EUnetHTA Project by
a transnational group working under considerable time pres-
sure, which caused procedural and quality problems. The
feedback will be used for further development of the HTA
Core Model and work processes within the EUnetHTA Col-
laboration.
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